Paid Advertisement
Despite significant advances in the diagnosis and management of transthyretin amyloid cardiomyopathy (ATTR-CM), delays in recognition and treatment initiation remain a critical barrier to optimizing patient outcomes. Because ATTR-CM often presents with non-specific symptoms and overlapping cardiovascular manifestations, many patients face a prolonged journey to an accurate diagnosis. Meanwhile, a rapidly expanding body of clinical evidence has made timely intervention, appropriate therapy selection, and comprehensive longitudinal care more essential—and complex—than ever.
Join us for this live symposium, held in conjunction with the American Heart Association (AHA) Scientific Sessions 2026, featuring a distinguished panel of nationally recognized ATTR-CM experts. Through interactive, case-based discussions, the faculty will provide actionable guidance to help you recognize key cardiac and extracardiac red flags, apply efficient diagnostic algorithms, and translate the latest clinical trial data into personalized management plans.
Key Learning Highlights:
- Early Recognition & Stepwise Diagnosis: Identify subtle red flags and implement streamlined pathways to shorten time-to-diagnosis.
- Mechanism & Evidence-Based Intervention: Understand how therapeutic mechanisms and clinical trial data inform therapy timing and selection across different disease stages and phenotypes.
- Individualized Management: Tailor treatment plans based on patient comorbidities, clinical presentation, and real-world considerations.
- Longitudinal Multidisciplinary Care: Monitor for signs of disease progression and coordinate care across specialties to optimize long-term outcomes.
Attendees will leave equipped with practical strategies for routine clinical practice and will receive the ATTR-CM Care Pathway Navigator—an expert-developed point-of-care resource designed to assist with diagnosis, treatment selection, and ongoing patient monitoring. Engage directly with expert faculty through live polling, audience discussion, and an interactive Q&A session.
This event is offered in conjunction with AHA Scientific Sessions Conference 2026 but is not part of the official program planned by the AHA Committee on Scientific Sessions Programming.